Most patients have reached their primary treatment objectives by this point
This stepwise approach means patients on lower maintenance doses may experience slower or less pronounced effects than those reaching higher therapeutic doses
Food and Drug Administration approved semaglutide (Wegovy) to reduce the risk of cardiovascular death, heart attack and stroke in adults with cardiovascular disease who have obesity or are overweight
However, you should follow NICE guidance for osteoporosis screening if you have additional risk factors such as being postmenopausal, having a history of fragility fractures, taking long-term corticosteroids, or experiencing rapid weight loss
If you miss a dose of tirzepatide, take it within four days (96 hours) if possible
You should also consult your GP if side effects don't improve after the expected adjustment period, or if they worsen despite implementing management strategies